NYSE: CHE

Chemed (CHE) Stock Analysis & Forecast

Nov 13 close

$548.20−2.00 (−0.4%)

Gekko Brief

AI summaryNov 9 close

Chemed shares reported higher net income and earnings per share for the third quarter and first nine months of 2026, with one summary citing a share price near $528.05 and a year-to-date return of 24.6%. The company also presented at the 2026 UBS Global Healthcare Conference and declared a quarterly dividend of $0.70 per share, marking its 222nd consecutive quarterly dividend, payable 4 December 2026 to shareholders of record 16 November 2026. Several filings this week disclosed insider stock sales by executives, including the CEO and an executive vice president, occurring while shares traded near their 52-week high.

Chemed closed at $538.06, up 1.9%, sitting above both its 50-day average of $514.86 and 200-day average of $465.36, with the 50-day above the 200-day. The stock's one-month return stands at 7.7% and its six-month return at 27.7%, with a 52-week high of $562.24 and low of $365.21. The GekkoIndex reads 52.8, placing it in the Neutral zone, while price sits 7.9% below the Gekko Fair Value of $584.08.

Chemed's next earnings date falls on 24 February 2027, 101 days away, outside a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in their respective 90-day and 30-day windows. Seasonality data show the next 20 trading days have averaged a 0.2% return over 5 years, rising in 2 of them. Analyst coverage from 5 firms shows 3 buy and 2 hold ratings, with a consensus target of $617 implying 14.7% upside, worth noting alongside the current Fair Value gap.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Chemed price vs fair value

$564.21$548.20Nov ’25May ’26Nov ’26
Close $548.20200-day averageGekko Fair Value $564.21

Chemed quick facts

Market cap
$7.13B
P/E ratio
26.4
Forward P/E
19.7
EPS, TTM
$20.88
Revenue, TTM
$2.66B
Profit margin
10.6%
Dividend yield
0.45%
Beta
0.49
Volume
73,494 avg 154,598
1-year return
+22.5%
Typical daily move
±3.3%
Typical 20-day move
±3.7%
50-day average
$517.08
200-day average
$467.59
Next earnings
Feb 24
Shares outstanding
12.96M
52-week range
$365.21$562.24

Chemed swing-trade checklist

Chemed scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive3 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $548.20 is above the 50-day ($517.08) and 200-day ($467.59) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    52.7, Neutral

    Reading 52.7 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    2.8% below

    Price is within 5% of Gekko Fair Value (2.8% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +0.9% on average

    From this point in the calendar, the next 20 trading days averaged +0.9% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Chemed stock chart and price history

Chemed closed at $548.20 on Nov 13, 2026, +22.5% over the past year, inside a 52-week range of $365.21 to $562.24.

Close50-day average200-day averageVolume
Chemed share price, past year, with 50-day and 200-day moving averages and volume$400$450$500DecJan 2026FebMarAprMayJunJulAugSepOctNov548.20

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+6.4%
3 months
+4.4%
6 months
+26.2%
1 year
+22.5%
The full CHE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CHE in Gekko

Follow Chemed through every session

Put CHE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track CHE in GekkoFree for 7 days. No credit card required.

About Chemed

Chemed brings together support for people in the final stages of illness, pairing medical treatment with emotional and spiritual comfort for patients and the families around them. The work is carried out by a mix of physicians, nurses, aides, social workers, clergy and volunteers. The company is also active in a completely different trade, fixing pipes, clearing drains, digging excavations and repairing water damage for homes and businesses.

These two very different activities sit under separate arms of the business, VITAS and Roto-Rooter. VITAS focuses on hospice and palliative care, largely within the United States, while Roto-Rooter reaches its customers through branches it owns directly as well as independent contractors and franchise partners, covering both households and commercial clients.

Founded in 1970, Chemed is based in Cincinnati, Ohio, and its stock trades on the NYSE under the ticker CHE.

Listed
NYSE
Sector
Health services
Industry
Hospital/Nursing management
Website
chemed.com

Chemed GekkoIndex: the smart money zone

Chemed’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.7, in the Neutral zone, down 1.5 points over five sessions.

010052.7Neutral

Down 1.5 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying39+0.8%+0.8%−0.2%+2.1%
Accumulation2660.0%−0.1%+0.1%+0.3%
Neutral (current zone)363−0.1%−0.1%−0.4%−1.8%
Distribution33+0.4%+0.5%+0.6%−0.5%
Selling1Too few readings yet

Average CHE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the CHE price, zone by zone.Track CHE in Gekko

Is Chemed stock overvalued? Gekko Fair Value

Chemed trades 2.8% below Gekko Fair Value of $564.21, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Chemed shares are worth, recalculated every trading day.

$564.21

Gekko Fair Value, Nov 14, 2026

2.8% below fair value · About fair value

At the end of Aug 2026 the price was 7.4% below the estimate.

Gekko Fair ValueShare price, month end
$564$548Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open CHE in Gekko

Chemed insider and Congress trading

No open-market insider purchases were filed for Chemed, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for CHE in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every CHE insider filing, plotted on the chart in Gekko.Open CHE in Gekko

Congress trades last 90 days

No trades in CHE were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for CHE, plotted on the chart in Gekko.Open CHE in Gekko

Buybacks

Chemed has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$62.52M
As a share of market cap
0.88%
Trailing four quarters
$524.6M

From company filings.

Chemed earnings: next date and track record

Chemed reports on Feb 24, 2027 (101 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±7.8%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−0.1%Jul ’24−12.0%Oct ’24+6.4%Feb ’25−5.6%Apr ’25−10.6%Jul ’25+6.6%Oct ’25−15.3%Feb ’26+5.9%Jul ’26

Last earnings call, Jul 28, 2026 AI summary

What they said
VITAS Healthcare exceeded high-end expectations in Q2 2026, with admissions of 19,125 (up 9% YoY) and higher-than-expected revenue growth and EBITDA margins while adding $8.9M to Florida cap cushion. Roto-Rooter showed mixed results: commercial revenue grew 6.8% YoY with commercial business manager branches up 13%, but marketing costs rose $3.1M due to declining free leads (-13.1%) and rising paid leads (59% of total vs. 54% prior year). Roto-Rooter acquired south Texas franchise assets for ~$12M.
Guidance
Management expressed increased confidence that VITAS has returned to normalized growth following the 2025 Florida cap issue. No specific revenue or EPS targets were provided in this excerpt, but tone suggests continued expansion of commercial business manager program at Roto-Rooter.
ReportedEPSSurpriseRevenueSurpriseMove
Jul 28, 2026$6.06
est $5.60
+8.2%$673.3M
est $665.0M
+1.2%+5.9%
Feb 25, 2026$6.42
est $7.02
−8.5%$639.3M
est $659.1M
−3.0%−15.3%
Oct 28, 2025$5.27
est $5.39
−2.2%$624.9M
est $659.0M
−5.2%+6.6%
Jul 29, 2025$4.27
est $4.78
−10.7%$618.8M
est $631.1M
−2.0%−10.6%
Apr 23, 2025$5.63
est $5.55
+1.4%$646.9M
est $641.8M
+0.8%−5.6%
Feb 26, 2025$6.83
est $6.78
+0.7%$640.0M
est $636.1M
+0.6%+6.4%
Oct 29, 2024$5.64
est $5.76
−2.1%$606.2M
est $636.1M
−4.7%−12.0%
Jul 24, 2024$5.47
est $5.59
−2.1%$595.9M
est $599.2M
−0.6%−0.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Chemed stock forecast and analyst price targets

Analysts’ average 12-month price target for Chemed is $617.00, +12.6% from the last close, from 5 firms rating the stock in the last 90 days.

$617.00consensus 12-month target, +12.6% from the last close
Low $555High $675
Buy3
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 5 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12OppenheimerBuy, maintained$625+14.0%
Oct 29OppenheimerBuy, reiterated$625+14.0%
Oct 29UBSBuy, reiterated$675+23.1%
Oct 28RBC CapitalHold, maintained$585+6.7%
Oct 28Bank of America SecuritiesHold, reiterated$555+1.2%
−0.4%average 20-day move after past Neutral readings
+0.9%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Chemed seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Chemed averaged +0.9% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

+2.9%2021+5.1%2022−0.4%2023−2.7%2024−1.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.2%3 of 5
Next 10 trading days−0.8%3 of 5
Next 15 trading days−0.8%1 of 5
Next 20 trading days+0.9%2 of 5
Next 30 trading days+0.5%2 of 5

For scale, CHE’s typical 20-trading-day move in either direction is about 3.7%.

Chemed market cap and key statistics

Chemed’s market cap is $7.13B, with a P/E ratio of 26.4 and revenue of $2.66B over the last twelve months.

Valuation

Market cap
$7.13B
P/E ratio
26.4
Forward P/E
19.7
EPS, TTM
$20.88
Gekko Fair Value
$564.21

Trading

Volume
73,494
Avg volume, 20 days
154,598
52-week high
$562.24
52-week low
$365.21
Shares outstanding
12.96M

Financials

Revenue, TTM
$2.66B
Profit margin
10.6%
Return on equity
29.1%
Quarterly earnings growth, YoY
+22.2%

Risk and income

Beta
0.49
Typical daily move
±3.3%
Typical 20-day move
±3.7%
Dividend yield
0.45%

Chemed stock news this week

Coverage of Chemed this week reads neutral: 3 positive, 8 neutral and 1 negative headlines.

News sentiment neutral

Chemed peers

Chemed’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
HCAHCA Healthcare−1.1%Neutral26.1% above
THCTenet Healthcare−0.8%Neutral3.0% below
UHSUniversal Health Services+1.0%Neutral11.5% below
PACSPACS0.0%Neutral6.5% below
SGRYSurgery Partners+1.1%Distribution45.2% above
NHCNational HealthCare−1.6%Accumulation18.9% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Hospital/Nursing management

Chemed stock FAQ

What is Chemed’s market cap?

Chemed’s market cap is $7.13B at the Nov 13, 2026 close of $548.20, with 12.96M shares outstanding. The shares trade on a P/E ratio of 26.4.

What is the Chemed stock forecast?

The consensus analyst 12-month price target for Chemed is $617.00, +12.6% from the last close. Of the 5 firms that rated the stock in the last 90 days, 3 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Chemed stock overvalued or undervalued?

On Gekko’s estimate Chemed is about fair value: the Nov 13, 2026 close of $548.20 is 2.8% below Gekko Fair Value of $564.21. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Chemed report earnings next?

Chemed is expected to report on Feb 24, 2027 (101 days away). Analysts expect earnings of $7.32 per share on revenue of $711.9M. Chemed beat the earnings estimate in 3 of its last 8 reports, moving 7.8% on average across the report.

What is Chemed’s 52-week high and low?

Chemed’s 52-week high is $562.24 and its 52-week low is $365.21; it closed at $548.20 on Nov 13, 2026, +22.5% over the past year. Over the last five years the shares peaked at $654.62 on Mar 15, 2024.

Is Chemed stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 3 as mixed (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Chemed the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.